Stock analysts at StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Rating) in a research note issued to investors on Friday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, Maxim Group lowered Aethlon Medical from a “buy” rating to a “hold” rating in a report on Tuesday, November 15th.
Aethlon Medical Trading Up 8.2 %
NASDAQ:AEMD opened at $0.44 on Friday. The firm has a market cap of $7.25 million, a PE ratio of -0.56 and a beta of 0.89. The stock has a fifty day moving average price of $0.57 and a 200 day moving average price of $0.95. Aethlon Medical has a 12-month low of $0.39 and a 12-month high of $2.73.
Institutional Inflows and Outflows
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
- Get a free copy of the StockNews.com research report on Aethlon Medical (AEMD)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.